Compare State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs Viatris Inc — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.22 (market cap $4.35B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 4.6× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and Viatris Inc pays a 2.75% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days and Viatris Inc for 57 Days on average.
| SJNK | VTRS | |
|---|---|---|
Market Cap | $4.35B | $20.03B |
Volume | 3,211,044 | 14,109,977 |
Sector | Fixed Income | Health |
52-Week High | $25.57 | $18.27 |
52-Week Low | $24.13 | $9.74 |
Typical Hold Time | 41 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJNK (SPDR Bloomberg Short Term High Yield Bond ETF) trades at $24.21, showing minimal daily movement with a 0.04% gain. Technical indicators signal bearish momentum with moving averages heavily favoring selling pressure, though oscillators remain neutral. The ETF continues its dividend distribution pattern with recent payments of $0.14-$0.15 per share. Institutional activity shows mixed sentiment with Cetera Investment Advisers maintaining a $17.83 million position while Balefire LLC significantly reduced its holdings by 74.7% in recent quarters.
The ETF faces headwinds from bearish technical signals despite attractive yield comparisons to Treasury bonds. Current price consolidation near $24 support levels suggests cautious investor sentiment. Dividend consistency provides income appeal, but institutional selling pressure and technical weakness indicate near-term challenges for price appreciation amid competitive fixed-income alternatives.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
